English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)

The Immuno-Oncologic Therapeutic area of Italfarmaco is acknowledged by the Italian oncologic community as a reference point in the specialist sector thanks to the originality of its products, the innovative pharmaceutical solutions and the innovation of experimental protocols.

Hematology and oncology

Italfarmaco has always developed products for the treatment of tumors and patient support through a constant partnership with Scientific Societies and the most qualified research groups in the oncologic area (solid tumors) as well as in the hematologic area (leukemia, myelomas, lymphomas, bone marrow transplantation). Thanks to the support offered by clinical research, the products manufactured by Italfarmaco today have a scientific literature authoritatively documenting its efficacy and safety extended to all these clinical settings.

Rare deseases

Italfarmaco holds the international patent and exclusivity of the first formulation of riluzole in oral suspension (Teglutik), a drug specifically indicated in the treatment of Amyotrophic Lateral Sclerοsis (ALS), a severely disabling disease. The formulation is the result of Italfarmaco's expertise in pharmaceutical technology and helps to respond to the problems of patients with swallowing disorders (dysphagia) or in enteral nutrition, in whom adherence to treatment is often compromised by the evolution of the disease.

In 2019, Italfarmaco strengthened its presence in the field of rare diseases with the medicinal specialty Votubia, based on the active ingredient everolimus, indicated in the treatment of certain cerebral complications of a rare genetic disease, "Tuberous Sclerosis". For this indication, Votubia was designated an 'orphan drug' in 2010.

Treatment of tumors

The company has a well-established experience and expertise in the therapeutic area of endocrinology and neuroendocrine tumors.

Supportive care in oncology and hematology

Nausea, vomiting, serious chronic pain and neutropenia, causing frequent, often fatal infections, represent the feared and severe complications of chemotherapeutic treatment in patients with tumors, resulting in a worsened Quality of Life or the impossibility of continuing their medical treatment.

The Immuno-oncologic therapeutic area of Italfarmaco has always been acknowledged for its innovative products and its constant support to clinical research aimed at optimizing tumor response to treatment and give patients the best possible life conditions.